Current Issue

Archives

Guidelines for Authors

Classified Ads

Subscriptions

Contact Info

Email Alert Service

Links

Secondary Health Service Care and Second Line Drug Costs of Early Inflammatory Polyarthritis in Norfolk, UK

ABSTRACT.

Objective. To estimate the secondary health service care and second line drug costs (including drug monitoring costs) for a cohort of people with early inflammatory polyarthritis (IP) and the subgroup classified as having rheumatoid arthritis (RA) recruited to a population based register.

Methods. The study population consisted of 344 people with IP who had enrolled on the Norfolk Arthritis Register (NOAR) in 1990-91, an average of 24 weeks after onset of their symptoms. Utilizing resource use data from NOAR, augmented by unit cost data from other sources, the average (per person) and cumulative secondary care and second line drug costs were estimated for Years 1, 2, 3, 4, and 5 following registration with NOAR.

Results. The total secondary health service care and second line drug costs were £472,125 (£338,704 for RA subgroup) (1990-91 prices) over the 5 year study period, with inpatient stays, outpatient visits, and second line drugs accounting for 58, 9, and 33%, respectively. Nineteen percent of the study population neither visited hospital nor were prescribed second line drugs.

Conclusion. Overall, inpatient stay costs represented the largest proportion of secondary health service care and second line drug costs, making 21% of the total study cohort responsible for 80% of the total 5 year costs incurred. (J Rheumatol 2000;27:2115–22)

Key Indexing Terms:

COST-OF-ILLNESS
COSTS
ECONOMICS
SECOND LINE DRUGS
SECONDARY HEALTH SERVICE CARE
INFLAMMATORY POLYARTHRITIS